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Abstract
Schistosomiasis is a neglected tropical disease that is responsible for almost 300,000 deaths annually. Mass drug
administration (MDA) is used worldwide for the control of schistosomiasis, but chemotherapy fails to prevent reinfection
with schistosomes, so MDA alone is not sufficient to eliminate the disease, and a prophylactic vaccine is required. Herein, we
take advantage of recent advances in systems biology and longitudinal studies in schistosomiasis endemic areas in Brazil to
pilot an immunomics approach to the discovery of schistosomiasis vaccine antigens. We selected mostly surface-derived
proteins, produced them using an in vitro rapid translation system and then printed them to generate the first protein
microarray for a multi-cellular pathogen. Using well-established Brazilian cohorts of putatively resistant (PR) and chronically
infected (CI) individuals stratified by the intensity of their S. mansoni infection, we probed arrays for IgG subclass and IgE
responses to these antigens to detect antibody signatures that were reflective of protective vs. non-protective immune
responses. Moreover, probing for IgE responses allowed us to identify antigens that might induce potentially deleterious
hypersensitivity responses if used as subunit vaccines in endemic populations. Using multi-dimensional cluster analysis we
showed that PR individuals mounted a distinct and robust IgG1 response to a small set of newly discovered and well-
characterized surface (tegument) antigens in contrast to CI individuals who mounted strong IgE and IgG4 responses to
many antigens. Herein, we show the utility of a vaccinomics approach that profiles antibody responses of resistant
individuals in a high-throughput multiplex approach for the identification of several potentially protective and safe
schistosomiasis vaccine antigens.
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Introduction
Schistosomiasis is a chronic, often debilitating, parasitic disease
affecting over 200 million people worldwide and killing at least
300,000 people annually [1]. The disability adjusted life years
(DALYs) lost to schistosomiasis are potentially as high as 70 million
[2,3]. Adult flukes live in the portal and mesenteric veins
(Schistosoma mansoni and S. japonicum) or in the veins of the bladder
(S. haematobium), as male/female pairs, and survive for many years
producing hundreds of fertilized eggs per day. Severe morbidity
results from the host immune responses to eggs that become
trapped in the tissues, including periportal fibrosis, portal
hypertension, urinary obstruction and bladder carcinoma [4].
Currently, chemotherapy with praziquantel (PZQ) is the
standard treatment for schistosomiasis. Control programs based
on mass drug administration (MDA) with PZQ have been
complicated by rapid and frequent re-infection of treated
individuals, and the difficulties and expense of maintaining
continuous MDA over the long term [5]. Additionally, resistance
to PZQ can be induced in the laboratory [6], and field isolates
displaying reduced susceptibility to the drug have been reported
(reviewed in [7]). Despite recent large-scale MDA efforts [8],
integrated control programs aimed at limiting schistosomiasis by
improving education and sanitation, molluscicide treatment
programs to reduce the population of the intermediate snail host,
and chemotherapy have had limited success [5,9]. A vaccine that
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induces long-term immunity to schistosomiasis is therefore
necessary to reach our goals of elimination.
The high prevalence of chronic schistosomiasis in endemic
populations suggests that sterile immunity is rarely generated.
However, the decline in infection intensity at an earlier age in
populations with high infection intensity [10], and more rapid
development of resistance to re-infection after several rounds of
PZQ treatment (drug-induced resistance) [11], indicates that non-
sterilizing immunity, though slow to develop, can occur. Despite
the slow acquisition of non-sterile immunity over time, there is still
an urgent need for a prophylactic vaccine, particularly one that
targets children, who represent the most at-risk population.
There are two major obstacles to the development of an
efficacious schistosomiasis vaccine. The first is the ability of
schistosomes to employ a range of strategies for evasion of the host
immune response. Central to the parasite’s ability to evade
immune clearance is its unique host-interactive outer surface, or
tegument, consisting of a single, contiguous, double-bilayered
membrane that covers the entire worm [12]. At this interface
essential functional interactions with the human host occur, such
as nutrient uptake and environmental sensing. The tegument is
also the primary site where the parasite defends itself against
immune recognition. The host-interactive surface is indeed the
target of the few successful examples of metazoan parasite
vaccines, such as those targeting the cattle tick Boophilus microplus
[13], the gastrointestinal nematode Haemonchus contortus [14] and
the cestodes, Taenia ovis [15] and Echinococcus granulosus [16]. The
second major obstacle to the development of a schistosomiasis
vaccine resides in the historic approach to antigen discovery for
this pathogen. To date, only one schistosomiasis vaccine,
rSh28GST from S. haematobium, is currently in phase I clinical
trials, where it was shown to be safe and immunogenic [17]. Other
vaccine antigens for S. mansoni are in pre-clinical and clinical
development [18,19], with safety and immunogenicity results yet
to be reported. We [19–21] and others [22,23] have advocated for
the utility of tegument proteins as a basis for subunit vaccines
against schistosomiasis. Three of the current lead candidate
antigens are located in the tegument and are exposed on the
surface of the parasite [24–26]. The genomes for the three major
human schistosomes have been sequenced [27–29], and coupled
with proteomic studies that characterised the surface proteomes of
S. mansoni [30] and S. japonicum [31], have provided researchers
with a catalogue of proteins for discovery and development of a
new panel of vaccine antigens.
To best mine this extensive proteomic data and identify antigens
that are preferentially recognised by antibodies from naturally
resistant individuals resident in areas of high transmission for
schistosomiasis, we have utilized a clinical cohort of individuals
referred to as Putative Resistants (PRs). As part of a ten year
longitudinal study of individuals from high S. mansoni transmission
areas of Brazil, we identified a cohort of individuals who were
constantly exposed to S. mansoni infection as determined by
extensive water contact and epidemiological studies, but remained
egg-negative over the course of the study [32–34]. In addition to
this unique epidemiological profile, these individuals mounted an
immune response that displayed a markedly different phenotype
from that of chronically infected (CI) individuals [35–37]. Indeed,
two of the current antigens in pre-clinical development - Sm-TSP-2
[26] and Sm29 [24] – were discovered as a result of their selective
recognition by PR subjects, highlighting their utility as a tool for
discovery of protective vaccine antigens.
Herein, we describe the screening of the first protein microarray
for a human helminth parasite, and only the second such array for
a eukaryotic parasite other than Plasmodium sp. We developed a
targeted array consisting primarily of tegument derived proteins
from both S. mansoni and S. japonicum [38]and screened the array
with sera from PR and CI individuals with low, medium and high
intensity infections, and then compared and contrasted antibody/
antigen recognition profiles to determine antibody signatures that
characterised natural resistance or susceptibility to infection. We
assessed IgG subclass and IgE responses such that potential
vaccine antigens could be assessed for their protective properties as
well as their safety profiles in terms of exacerbating allergic IgE
responses [39]. We showed that individuals with medium and
heavy intensity infections generally recognized more antigens and
with higher magnitude than did PR individuals and those with low
infection intensities. Moreover, we found that PR individuals did
not mount an intense IgE response to these antigens compared to
CI individuals, but instead produced IgG1/3 (cytophilic) antibody
responses to only a few membrane bound antigens. We
successfully utilized this approach to identify new, and confirm
existing, vaccine antigens via their selective IgG1/IgG3 recogni-
tion profiles by PR individuals in the absence of a potentially
deleterious IgE response.
Results
Schistosome protein microarray production and quality
control
Details of the microarray production and associated QC
have been described elsewhere [38] and are shown in Figure S1
and Table S1, however this is the first report that describes
probing of the microarray with human sera. We included on
the array two dilutions of the ubiquitously immunoreactive
Epstein Barr virus protein EBNA-1 at two concentrations, 0.1
and 0.3 mg/ml, as a non-schistosome control for the rapid
translation system (RTS) used to express schistosome recombi-
nant proteins. Both antigens were consistently recognized by
IgG1 antibodies from all individuals tested (Figure S2),
indicating that sera from all cohorts were of sufficient integrity
for further analyses.
Author Summary
Schistosomiasis is a neglected tropical disease that kills as
many as 300,000 people each year. Mass drug administra-
tion is widely used to control schistosomiasis, but fails to
prevent rapid reinfection in endemic areas. There is a
desperate need for a prophylactic vaccine; however, very
few candidates have been developed. Herein, we take
advantage of recent advances in systems biology and
longitudinal studies in schistosomiasis endemic areas to
pilot an immunomics approach to the discovery of vaccine
antigens. The emerging field of immunomics enables the
determination of an ‘‘antibody signature’’ to a pathogen
proteome for both resistant and susceptible individuals.
We constructed the first protein microarray for a multi-
cellular pathogen and probed it with sera from naturally
resistant vs. susceptible individuals from a high transmis-
sion area in Northeastern Brazil. Using multi-dimensional
cluster analysis, we showed that resistant individuals
mounted a distinct and robust IgG1 antibody signature
to a small set of newly discovered and well-characterized
surface antigens in contrast to infected individuals. This
antigen discovery strategy can lead to identification of
several potentially protective and safe schistosomiasis
vaccine antigens.
Schistosome Immunomics for Vaccine Discovery
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Antibody profiles correlate with infection intensity
Given the distinct roles of different immunoglobulin isotypes
and IgG subclasses in chronic helminth infections, and to gain a
comprehensive picture of antibody reactivity from PR versus CI
individuals, we analyzed IgG1, IgG3, IgG4 and IgE responses to
soluble worm antigen preparation (SWAP) and a panel of
schistosome antigens. PR subjects mounted the strongest anti-
SWAP IgG1 and IgG3 responses whereas the moderate and
heavily infected groups mounted the strongest IgG3 responses to
SWAP (Figure S3). One hundred and sixteen (116) from a total of
215 (54%) RTS proteins spotted were recognized by at least one
antibody isotype/subclass from at least one cohort of exposed
individuals (reactive proteins) (Table S2 and Table S3). Individuals
with medium and heavy intensity infections generally recognized
more antigens and with stronger SI than did PR individuals and
those with low infection intensities (Figures 1A-D). CI-Mod and
CI-Heavy cohorts had significantly higher IgG4, IgG3 and IgE
responses than PR and CI-Light cohorts (Figures 1A-C) (*p,0.05;
**p,0.01, ***p,0.001, ****p,0.0001). In contrast, the PR
cohort had significantly higher IgG1 (Figure 1D) responses than
CI-Mod and CI-Heavy cohorts, although the total number of
antigens above the cut-off was lower for this antibody subclass. In
general, there was a strong correlation between infection intensity
and the number of antigens recognized by combinations of IgG3,
IgG4 and IgE from infected individuals (Table S4 and Table S5).
Of the 116 reactive proteins (RTS and recombinants) 41 were
recognized by just a single antibody isotype/subclass: 8 proteins
were recognized by only IgG1, 24 proteins were recognized by
only IgG3, one protein was recognized by only IgG4 and 10
proteins were recognized by only IgE. Eleven proteins were
recognized by all antibody isotypes/subclasses (Figure 1E) (Table
S2).
Figure 1. Isotype and subclass-specific antibody recognition profiles of PR and CI individuals to schistosome antigens printed on
the proteome microarray. The average adjusted signal intensity for IgE (A), IgG4 (B), IgG3 (C) and IgG1 (D) antibody responses of individual
protein microarray features Cohorts of individuals that are putatively resistant (PR) to S. mansoni infection, or have low (CI-Light), moderate (CI-Mod)
and heavy (CI-Heavy) intensity infections (based on eggs per gram of feces) were graphed. Red lines denote the cut-offs for each antibody isotype/
subclass calculated by determining the average of the signal intensity for control spots on the microarray that contained no DNA (No DNA controls).
Statistical analysis was performed using one-way ANOVA with Dunn’s multiple comparisons test. *p,0.05; **p,0.01, ***p,0.001, ****p,0.0001.
Venn diagrams (E) representing the combined data of Figures 1A-D. Values in the diagram show the protein microarray features recognized by each
isotype/subclass.
doi:10.1371/journal.ppat.1004033.g001
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IgE responses
IgE responses were detected to 79 different antigens (Figure 2,
Table S2) and most of these were restricted to the CI-Mod and CI-
Heavy groups. Significant differences (P#0.05) between mean
antibody responses from 2 or more of the endemic groups were
detected to all 79 proteins (Tables S2–4). The only purified
recombinant protein (non-RTS) that was the target of an IgE
response was Sm29. Antigens for which the strongest IgE responses
were detected included proteins that were predicted and/or
proven to be located on the tegument membrane (including
tetraspanins, Ly6/CD59-like proteins such as Sm29, and glucose
transporters) and predicted intracellular proteins including mito-
chondrial enzymes, chaperones and glycolytic enzymes such as
triose phosphate isomerase (Table S1 and Table S2).
IgG subclass responses
IgG4 responses were detected to 21 proteins (Figure 3) – 20
RTS proteins and purified recombinant Sm29 expressed in E. coli.
Significantly different IgG4 responses were detected for all reactive
antigens between at least two of the endemic cohorts (Table S3,
Table S4). Sm29 was recognized weakly by IgG4 but was
considered a cross-reactive protein because the US non-endemic
control group had a low level IgG4 response against this protein
(Figure 3, Table S2).
IgG3 responses were detected to 96 proteins, 95 of which were
RTS and 1 E. coli-derived purified recombinant proteins (Figure 4,
Table S2). Of the 96 reactive proteins, only 3 displayed no
significant differences between the cohorts (Figure 4, Table S4).
IgG1 responses were detected to 43 proteins (Figure 5, Table
S2), including purified recombinant Sm29 and Sm-TSP-2. Signif-
icantly different IgG1 responses between endemic cohorts were
detected for 31 of these reactive antigens (Table S4). Twenty-two
proteins were the targets of an IgG1 response in the PR cohort
that was significantly different to at least one of the CI groups
(Table S4). The most robust of these PR-specific IgG1 responses
were aimed at the two positive control recombinant proteins, Sm-
TSP-2 and Sm29, and the RTS protein Smp_139970, a
calmodulin-3 like protein that we have termed Sm-CAM-3. Sm-
CAM-3 shared 46% and 23% amino acid identities with its closest
S. mansoni and primate (macaque) homologues respectively (Figure
S4).
Correlations between different isotype responses to the same
proteins were calculated (Table S5). The strongest correlations
detected (r2.0.9) were between IgG4/IgE responses in all the
schistosome-exposed cohorts (P,0.0001, Figure S5) and IgG3/
IgG4 and IgG3/IgE responses in the CI-Mod and CI-Heavy
cohorts.
Cluster analysis
All the 215 proteins printed on the array were subjected to
cluster analysis to identify proteins with similar reactivity profiles.
Two different methods of unsupervised clustering were applied:
partitional and hierarchical clustering. Considering all of the
possible combinations of antibody reactivity patterns, we used
classical multidimensional scaling (MDS) cluster analysis to
generate clusters of proteins. In this analysis, the reactivity of
each protein was described with the average SI for each cohort.
Proteins with an average SI below the cut-off in the evaluated
group were considered to be zero and only proteins with an
average signal intensity above the cut-off for at least one isotype/
subclass were considered for clustering. For partitional clustering,
working with 4 antibody isotypes/subclasses and 5 cohorts,
proteins fell into one of 7 clusters determined by K-means
methodology [40]. To facilitate visualization of the process (and
avoid superimposing data points in a 2-dimensional format), we
compressed the 20 dimensions into just 2 dimensions (Figure 6A).
For hierarchical clustering, a dendrogram was designed using
complete linkage [41] to combine two proteins and color coded to
match the k-means clusters; identities of the proteins within each
cluster can be found in Table S2 and Figure S5. There was good
correlation between partitional and hierarchical clustering, indi-
cating that the division of proteins in these groups was robust. To
further enhance the visualization process, clustered proteins were
distributed in 2 dimensions based on isotype/subclass specific
responses of each cohort to each individual protein (Figure 6B).
A number of clusters of interest for vaccine development were
observed. Clusters 4 and 5 are characterized by proteins that are
moderate to strong targets of IgE and IgG3 or IgG1 responses,
respectively, particularly in the CI-Mod and CI-Heavy groups.
Cluster 7 predominantly consists of non-reactive proteins and a
small handful of proteins that were exclusively targeted by IgG1
responses of the individual sera in the PR group but not the CI or
non-endemic control groups. Of the strongly reactive PR IgG1
proteins, Sm29 was also recognized by all IgG subclasses as well as
IgE and belonged to cluster 2; Sm-TSP-2 and Sm-CAM-3 on the
other hand were uniquely targeted by PR IgG1 and not other
isotypes or subclasses and belonged to cluster 7 (Figure 6, Figure
S6 and Table S2). Other cluster 7 proteins that were uniquely
recognized by PR IgG1 responses, albeit relatively weak responses,
included Smp_124240 (Na/K transporting ATPase beta subunit)
and Sj_AY915291 (fatty acid CoA synthetase). Both of these
proteins have multiple predicted membrane spanning domains
(not shown).
Immune responses to current schistosome vaccine
antigens
We examined the antibody recognition profiles of individuals
within the cohorts to some of the current antigens that are under
various stages of pre-clinical development as human schistosomi-
asis vaccines, including Sm-TSP-2, Smp80 (calpain) and Sm14, and
bovine vaccines to interrupt zoonotic transmission (Sj23). We
compared the responses of these known vaccine antigens with
selected RTS proteins including the PR IgG1-specific target
Smp_139970 (Sm-CAM-3) and 2 proteins that were significant
targets of IgE and/or IgG4 in CI-Mod and CI-Heavy cohorts,
Smp_050270 and Smp_008310 (Figure 7). Different antigens
displayed distinct IgE and IgG subclass profiles. Sm-TSP-2 was the
target of a strong IgG1 response that was unique to the PR group,
Figure 2. IgE reactivity profiles of resistant and susceptible human cohorts to Schistosoma proteins printed on a proteome
microarray. Heatmap showing IgE responses of individual subjects (columns) in each cohort to 79 recombinant antigens (rows) printed on the
microarray. Green represents no immunoreactivity through to red symbolizing strong immunoreactivity. The bar graph depicts the average signal
intensity of each cohort. Proteins are ordered based on SI mean, highest to lowest, in the groups. Human cohorts represented: Putative Resistant
(n = 20), CI-Light (n = 30), CI-Mod (n = 18) and CI-Heavy (n = 17) non-endemic Brazilian volunteers (n = 12), non-endemic North American volunteers
(n = 12). The red line is the cut-off for reactivity, calculated as one standard deviation of the mean of the no-DNA control spots printed on the array
and probed with anti-IgE. All of the proteins showed significant differences between at least two of the schistosome exposed groups (PR, CI-Light, CI-
Mod and CI-Heavy) as calculated by Kruskal-Wallis test with Dunn’s multiple comparison post-test (Table S4).
doi:10.1371/journal.ppat.1004033.g002
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in agreement with the published literature [26]. Smp_139970 (Sm-
CAM-3) showed the same recognition profile as that targeting Sm-
TSP-2. Mean SI values for IgE were below the cut-offs for all of
the vaccine antigens, however varying numbers of individuals in
the CI-Moderate and CI-Heavy groups were positive for some of
the antigens, although SI values were weak compared with other
RTS proteins such as Smp_008310. Similarly, IgG4 responses
were mostly below the cut-off for the established vaccine antigens.
The mean IgG3 responses were mostly negative but weakly
positive for Smp80 and Sm-CAM-3 in the CI-Mod cohort. IgG1
responses to the known (and potentially new) vaccine antigens
were the most noteworthy in terms of unique recognition by the
PR cohort: strong IgG1 responses to both Sm-TSP-2 and Sm-
CAM-3 were detected in just the PR group and none of the CI
groups (Figure 7).
Discussion
Herein we describe the first immunomics-based approach to
study the humoral immune response to a multi-cellular pathogen.
Figure 3. IgG4 reactivity profiles of resistant and susceptible human cohorts to Schistosoma proteins printed on a proteome
microarray. Heatmap showing IgG4 responses of individual subjects (columns) in each cohort to 23 recombinant antigens (rows) printed on the
microarray. Green represents no immunoreactivity through to red symbolizing strong immunoreactivity. The bar graph depicts the average signal
intensity for each cohort. Proteins are ordered based on SI mean, highest to lowest, in the groups. Human cohorts represented: Putative Resistant
(n = 20), CI-Light (n = 30), CI-Mod (n = 18) and CI-Heavy (n = 17) non-endemic Brazilian (n = 12) and non-endemic North Americans (n = 12). The red line
is the cut-off for reactivity, calculated as one standard deviation of the mean of the no-DNA control spots printed on the array and probed with anti-
IgG4. NS represents no significant differences between endemic groups calculated by Kruskall Wallis with Dunn’s multiple comparison test. All other
proteins showed significant differences between at least two of the schistosome exposed groups (PR, CI-Light, CI-Mod and CI-Heavy) (Table S4).
doi:10.1371/journal.ppat.1004033.g003
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The ‘‘immunome’’ can be defined as the entire set of antigens or
epitopes that interface with the host immune system [42]. Recent
advances in high order multiplexing, or megaplexing, such as the
protein microarray discussed below, provide a practical, high-
throughput and affordable approach to estimating the immunomic
profiles of humans or animals to a pathogen [43,44]. This
approach permits investigators to assess the repertoire of
antibodies created in response to infections or vaccinations from
large collections of individual sera. Further, it can be used to
perform large-scale sero-epidemiological, longitudinal and sero-
surveillance analyses not possible with other technologies.
Numerous passive transfer studies [45,46] support the critical
role of antibodies in immunity to S. mansoni infection in rodent
models. Perhaps the most compelling evidence that the humoral
immune response targets the tegument and can kill parasites
comes from studies with rats, which are semi-permissive to S.
mansoni [47,48]. Resistance to schistosomiasis can be passively
transferred via serum from resistant rats, and protective antibodies
can be removed by adsorption on the surface of schistosomes [49].
Indeed, two of the recombinant antigens used on our array - Sm-
TSP-2 and Sm29 - have proven efficacious in a mouse challenge
model and were the major targets of single chain antibodies from
resistant rats adsorbed from the surface of live schistosomes [50].
The role of antibodies in protective immunity against schisto-
somiasis in humans is, however, somewhat contentious. Unlike
experimentally infected rats, protective immunity to schistosomes
in humans develops slowly (over many years) and is rarely
sterilizing in nature. Distinct molecular mechanisms are thought
be critical in the acquisition of immunity in different transmission
scenarios. For example, some individuals can successfully mount a
protective antibody-mediated response that targets adult S. mansoni
antigens after repeated rounds of PZQ therapy [51,52] – this drug-
induced resistance is mediated by IgE and T helper type 2 (Th2)
cytokines, and can be accelerated and augmented by repeated
drug treatment [11,53,54]. We show here that CI individuals
make robust IgE responses to many antigens, and the number of
antigens recognized increases with increasing intensity of infection
as measured by eggs per gram of feces. This would appear to
contrast with the protective role that is often associated with IgE in
helminth infections, including schistosomiasis [55].
In contrast to drug-induced resistance to schistosomiasis,
naturally acquired resistance has been reported in a subset of
people who have constant exposure to schistosomes but have never
been treated with PZQ (exemplified by the PR cohort in our study)
– these individuals generate robust T cell responses against the
surface of the larval schistosomulum and are characterized by
elevated levels of IFN-c [35,56–58]. We show here that PR
individuals, despite constant exposure to S. mansoni, do not appear
to mount a strong IgE response to the proteins on the array.
Unlike CI individuals, PR subjects are repeatedly negative for
schistosome eggs in the feces, and are therefore unlikely to receive
the IgE-inducing stimulus of eggs trapped in the bowel wall and
the subsequent hepato-portal inflammation that typifies
chronic schistosomiasis. PR individuals are likely to kill juvenile
schistosomes before they reach sexual maturity, either in the skin
or the lungs. The strong recognition of just a handful of tegument
antigens by IgG1 from PR individuals therefore implies a
protective role for IgG antibodies (and/or T cells) targeting these
proteins.
A major outcome of this study is the development of a tool by
which the immunogenicity and probable safety profile (i.e. IgE
recognition) of an antigen can be rapidly assessed, and a putative
association of that antigen-antibody interaction with resistance or
susceptibility to infection inferred. In terms of vaccine antigen
discovery, we employed the following principles to a given antigen:
(1) up-selection for further evaluation based on preferential
recognition by IgG1 and/or IgG3 from the PR but not the CI
cohorts; (2) down-selection based on recognition by IgE from
either PR or CI individuals. Our rationale for down-selection of
IgE-inducing antigens is primarily due to safety concerns [19]. In a
recent phase I clinical trial of the of the Na-ASP-2 hookworm
vaccine in a Necator americanus-endemic area of Brazil, hookworm
exposed individuals were vaccinated with a recombinant protein
which, despite proving safe and immunogenic in helminth-naı¨ve
individuals in the USA [59], induced an immediate hypersensi-
tivity (urticarial) response in vaccinees, resulting in suspension of
the clinical trial and further development of this antigen as a
vaccine [39]. The allergenicity of the hookworm vaccine was
linked to pre-existing IgE to parasite-derived Na-ASP-2 in the
circulation of exposed individuals. Rather than completely
excluding antigens that are the targets of pre-existing IgE
responses from further development as vaccine antigens, we
suggest that IgE antigens that associate with resistance might be
carefully progressed towards studies that assess their anaphylac-
togenic potential, particularly given the large body of data that
shows a protective role for IgE in resistance to human helminths.
For a vaccine targeting infants prior to natural exposure to
schistosome-infected water, a vaccine that incorporates antigens
which are the targets of IgE in older individuals is feasible, and
might even harness the putative protective capacity of this
immunoglobulin isotype as children first become exposed to the
parasite and undergo boosting and isotype class switching.
Using these criteria described above to set the parameters for
multi-dimensional clustering, a small number of antigens that
made up cluster 7 are noteworthy as targets of IgG1 from the PR
cohort but not IgE from any cohort. One of these antigens, Sm-
TSP-2, was already known to be a selective target of PR IgG
responses [26], and its recognition profile on the microarrays
served to confirm its potential as a vaccine antigen, as well as the
utility of our approach for identifying protective antigens. At least
three RTS proteins from cluster 7 were noteworthy as targets of
PR IgG1 but not IgE from any exposed cohort. Of these antigens,
the strongest IgG1 response was aimed at Smp_139970 (Sm-CAM-
3). Sm-cam-3 mRNA (and its S. japonicum ortholog, contig 8758) is
upregulated in cercariae [60,61] (Figure S4A) and encodes a
member of the calmodulin family of calcium-sensing proteins.
Calmodulins respond to changes in calcium ion concentrations by
undergoing a conformational change upon binding, which in turn,
Figure 4. IgG3 reactivity profiles of resistant and susceptible human cohorts to Schistosoma proteins printed on a proteome
microarray. Heatmap showing IgG3 responses of individual subjects (columns) in each cohort to 98 recombinant antigens (rows) printed on the
microarray. Green represents no immunoreactivity through to red symbolizing strong immunoreactivity. The bar graph depicts the average signal
intensity with mean standard deviation of each cohort. Proteins are ordered based on SI mean, highest to lowest, in the groups. Human cohorts
represented: Putative Resistant (n = 20), CI-Light (n = 29), CI-Mod (n = 17) and CI-Heavy (n = 17). non-endemic Brazilian (n = 10), non-endemic North
Americans (n = 12). The red line is the cut-off for reactivity, calculated as one standard deviation of the mean of the no-DNA control spots printed on
the array and probed with anti-IgG3. NS represents no significant differences between endemic groups calculated by Kruskall Wallis with Dunn’s
multiple comparison test. All other proteins showed significant differences between at least two of the schistosome exposed groups (PR, CI-Light, CI-
Mod and CI-Heavy) (Table S4).
doi:10.1371/journal.ppat.1004033.g004
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facilitates interactions with other signaling proteins. Using gene
silencing and quantitative parasite motility assays, a schistosome
calmodulin dependant kinase (CamKII) was shown to minimise
the impact of PZQ treatment against adult S. japonicum [62]. Sm-
CAM-3 is a small (,8 kDa) protein that contains a single Ca2+
binding EF-hand motif and shares moderate homology with
mammalian and other parasite calmodulins, the majority of which
are larger than Sm-CAM-3 and contain multiple EF-hands. Of the
four calmodulin family members present in S. mansoni, two have
been characterized (SmCaM1 and SmCaM2) and were detected in
the tegument of adult worms [30,63] and the epidermal and
tegumental layers of larval stages in the snail host [64]. Indeed
RNAi-mediated silencing of these genes resulted in stunted larval
development [64]. Generic calmodulin antagonists have been
Figure 5. IgG1 reactivity profiles of resistant and susceptible human cohorts to Schistosoma proteins printed on a proteome
microarray. Heatmap showing IgG1 responses of individual subjects (columns) in each cohort to 45 recombinant antigens (rows) printed on the
microarray. Green represents no immunoreactivity through to red symbolizing strong immunoreactivity. The bar graph depicts the average signal
intensity with mean standard deviation of each cohort. Proteins are ordered based on SI mean, highest to lowest, in the groups. Human cohorts
represented: non-endemic Brazilian (n = 12), Putative Resistant (n = 20), CI-Light (n = 30), CI-Mod (n = 18) and CI-Heavy (n = 17). The red line is the cut-
off for reactivity, calculated as one standard deviation of the mean of the no-DNA control spots printed on the array and probed with anti-IgG1. NS
represents no significant differences between endemic groups calculated by Kruskall Wallis with Dunn’s multiple comparison test. All other proteins
showed significant differences between at least two of the exposed groups (PR, CI-Light, CI-Mod and CI-Heavy) (Table S4).
doi:10.1371/journal.ppat.1004033.g005
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Figure 6. Immunoreactivity of Schistosoma proteins by multi-dimensional cluster analysis. (A) Multi-dimensional clustered distribution of
all proteins according to the antibody isotype/subclass responses in distinct cohorts. To identify clusters containing proteins with the same antibody
reactivity profiles, a distance matrix estimated from the pairwise Euclidian distance of log transformed signal intensity (SI) was generated for each
antigen based on the cut-off values for each antibody isotype/subclass in the different cohorts. Proteins formed 7 clusters, defined by the following
colors: cluster 1 - black (4 proteins); cluster 2 – blue (11 proteins); cluster 3 – grey (5 proteins); cluster 4 – green (31 proteins); cluster 5 – magenta (47
proteins); cluster 6 – orange (11 proteins) and cluster 7 – red (106 proteins). (B) Two-dimensional depiction of the average signal intensity for each
clustered interaction separated by antibody isotype/subclass and cohort. The dotted line represents the cut-off based on the no-DNA control spots.
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shown to inhibit the in vitro growth and egg-hatching ability of
schistosomes [64,65] and the growth of Plasmodium [66] but have
limited use as anti-parasitic interventions due to the highly
conserved nature of calmodulins across species. It is therefore
noteworthy that Sm-CAM-3 shares only ,20% identity with
primate calmodulins (Figure S4B), supporting its development as a
safe schistosomiasis vaccine that is unlikely to induce antibodies
which cross-react with homologous human proteins. Although Sm-
CAM-3 is immunogenic in PR individuals, it is a small protein and
might not be overly immunogenic as a subunit vaccine. An ideal
schistosomiasis vaccine might therefore incorporate Sm-CAM-3 as
part of a larger chimeric construct with other vaccine antigens
such as Smp80-calpain or Sm-TSP-2, a strategy that was recently
shown to boost efficacy in a mouse challenge model [67]. Two
other cluster 7 RTS proteins were unique targets of just IgG1 in
the PR cohort, albeit with relatively weak responses –
Smp_124240 (Na/K transporting ATPase beta subunit) and
Sj_AY915291 (fatty acid CoA synthetase). Both proteins have
multiple predicted membrane spanning domains, and warrant
expression of defined extracellular domains in a cell-based system
for further investigation as vaccine antigens.
In addition to Sm-TSP-2, two other high profile vaccine antigens,
Smp80-calpain (Smp_137410) and Sm14 (Smp_095360), were
contained within cluster 7. Although some individuals mounted
IgG and to a lesser extent IgE responses to these RTS products,
the mean SI values for any isotype/subclass to either antigen
were below the cut-offs. The apparent absence of a positive
mean SI (indicative of a strong antibody response) to an RTS
protein on the array should be treated with due caution – the
benefit of RTS protein production is its inherent high-
throughput nature and its suitability for printing onto arrays
in nanoliter quantities. One of the major limitations of RTS
protein production however is the absence of complex secretory
machinery and the dependence on secretory pathways for
correct folding and processing of some proteins. While there are
RTS systems that contain eukaryotic microsomal membranes,
these systems are not widely used for protein microarray
production, and would add substantial cost to the production of
large arrays. Sm-TSP-2 was available to us in recombinant, cell-
derived form, and was not successfully translated in RTS form.
Smp80-calpain and Sm14 were successfully produced in RTS
form (Figure S1), but we cannot guarantee faithful replication of
all the native epitopes. We therefore urge caution in the
interpretation of a ‘‘negative’’ result using this microarray
approach, but we have confidence in assigning a ‘‘positive’’
antibody response.
Proteome microarrays have been used to identify candidate
vaccine antigens for a number of infectious diseases of viral and
bacterial origin [43]. To date, Plasmodium is the only eukaryotic
parasite for which proteome microarrays have been described
[68]. Screening of P. falciparum proteome arrays with sera from
well-defined clinical cohorts resident in malaria-endemic areas
[68–70] and recipients of radiation attenuated vaccines [71] has
resulted in the identification of a suite of new vaccine antigens,
some of which have proven efficacious in mouse models of malaria
(DLD, unpublished observations).
Our proteome microarray included a small number of carefully
selected S. mansoni and S. japonicum proteins, working on the
assumption that tegument surface proteins are most likely to be the
targets of PR protective immune responses. Based on our findings
here, notably the large number of immunogenic proteins, a second
generation array that consists of a much larger number of S. mansoni
proteins, both extracellular and intracellular, would likely yield
many more immunogenic proteins, including potential vaccine
and diagnostic antigens. This is particularly relevant in the context
of antigen discovery using sera from individuals who have
developed resistance to schistosomiasis after repeated rounds of
PZQ therapy (drug induced resistance - DIR), where the immune
response is primarily aimed at intracellular molecules released by
dying worms [72] or other means of protein export such as
exosomes [73]. We are now screening our array (and subsequent
generation arrays) with sera from DIR individuals. Indeed, if a
schistosomiasis vaccine is developed, it is likely to be incorporated
into an integrated control program that couples chemotherapy
with vaccination [19], so a comprehensive assessment of the
targets of DIR immunity will prove to be an essential component
of future schistosomiasis vaccine antigen discovery.
We have shown here that proteome microarrays provide an
ideal means by which to explore humoral immunity and vaccine
antigen discovery for parasitic helminth infections. The approach
is less labor intensive and more sensitive than traditional
immunoproteomics based approaches that employ 2D Western
blots followed by protein extraction from SDS gels [72].
Moreover, antigens can be readily up-selected for their protective
properties and down-selected for potentially deleterious allergic
properties, in a high-throughput fashion with large numbers of
sera. The power of this technology lies with the nature of the
assembled cohorts – whether they are well-characterized groups of
naturally resistant and susceptible individuals, or animals that have
been experimentally rendered resistant by vaccination (e.g.
irradiated schistosome cercariae [74,75]). With the recent
sequencing of the S. haematobium genome [27], and the enormous
burden of disease that is attributed to urogenital schistosomiasis in
Sub-Saharan Africa [76], it is now essential to apply a systems
vaccinology approach to the integrated control of all the major
schistosomes infecting humans. Future efforts will explore the
replication of conformational epitopes in prokaryotic (as done
herein) versus eukaryotic (eg. insect cell lysates) RTS systems, and
larger protein microarrays containing the entire parasite secretome
will be produced to allow a more comprehensive screen and
ensure that a pipeline of schistosomiasis vaccine antigens is
generated for progression towards clinical trials.
Materials and Methods
Ethics statement
All subjects provided written informed consent using forms
approved by the Ethics Committee of Centro de Pesquisa Rene´
Rachou (reference number Fev/04), the Federal Institutional
Review Board of Brazil or CONEP (25000.029.297/2004-58) and
the George Washington University School of Medicine Institu-
tional Review Board (GWUMC IRB# 100310).
Study cohorts
Individuals aged 18–60 (inclusive) from a S. mansoni endemic
areas in Minas Gerais State, Brazil were followed longitudinally.
Individuals were determined to be Putative Resistant (PR) if they
had regular contact with infected water as determined by water
contact studies and surveys for infected snails [26], and no
S. mansoni eggs in their feces after three days of examination of
Proteins with signal intensity below the cut-off were set to zero to decrease background noise. Identities of proteins within clusters are provided in
Tables S1 and S2 and Figure S5.
doi:10.1371/journal.ppat.1004033.g006
Schistosome Immunomics for Vaccine Discovery
PLOS Pathogens | www.plospathogens.org 11 March 2014 | Volume 10 | Issue 3 | e1004033
Figure 7. Immunoreactivity of current schistosomiasis vaccine antigens printed on the microarray. Signal intensity values depicting
isotype/subclass-specific antibody responses of individual subjects in each cohort to proteins corresponding to known schistosomiasis vaccine
antigens and other select RTS proteins that were spotted on the microarray - Sm-TSP-2, Sm-14, Sj-23 and Smp80. Three new RTS antigens from S.
mansoni were also included: Smp_139970, Smp_050270 and Smp_008310. Only groups from the schistosomiasis endemic area are represented:
Putative Resistant (PR - blue), S. mansoni chronically infected with low (CI-Light – orange), moderate (CI-Mod - purple) and high (CI-Heavy - gray)
intensity infections. The red line is the cut-off calculated as one standard deviation of the no-DNA control spots printed on the array and probed for
each specific antibody isotype/subclass.
doi:10.1371/journal.ppat.1004033.g007
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fecal samples by ether sedimentation and Kato Katz fecal thick
smears (2 slides per fecal sample) over a period of 10 years of
investigation (n = 20). The PR group were matched with sera
taken from individuals deemed to be chronically infected (CI) with
S. mansoni as determined by the fecal exam methods described
above and stratified in the following groups by the intensity of S.
mansoni infection as expressed in eggs per gram of feces (epg) by
Kato Katz fecal thick smear: CI-Light (n = 30; epg ,100), CI-
Moderate (n = 20; epg = 101–400) and CI-Heavy (n = 20;
epg.401). Individuals in each CI intensity strata were age, sex,
and water contact matched with a PR individual. The PR and
some of the CI sera were the same as those used in Tran et al. [26].
We included negative control groups from non-endemic areas of
both Brazil (Belo Horizonte, Minas Gerais; n = 12) and the U.S.
(n = 12). Donor sera from the U.S. were taken at the George
Washington University under an IRB approved protocol. Table
S6 contains the demographic information on the different cohorts
utilized in this study.
Recombinant protein expression and printing
A subset of potentially immunogenic open reading frames
(ORFs) were selected for expression and printed from publically
available coding sequences for S. mansoni (n = 63) and S. japonicum
(n = 214) [38]. Most of these sequences were selected based on
bioinformatic, proteomic and transcriptomic data using the
following criteria: high sequence homology among the two
schistosome species; expression in the immunologically vulnerable
schistosomulum stage; predicted or known to be localized on or in
the parasite tegument; and limited sequence similarity with
mammalian homologs. Primer design and PCR amplification
from S. mansoni and S. japonicum cDNA libraries were performed as
described [38]. Amplicons were cloned into the custom made pXi
T7 vector containing N-terminal 10-His and C-terminal HA tags
by homologous recombination, as described previously [77]. Of
the sequences selected, 88% (n = 244) were successfully amplified
and the resultant plasmids purified, and the inserts were verified by
PCR and sequencing [38] (Table S1). A total of 217 high-yielding
plasmids (45 from S. mansoni and 172 from S. japonicum) with correct
inserts were expressed in an in vitro cell-free system based on
Escherichia coli ribosomes (Roche RTS 100), and the protein
extracts were contact-printed without purification onto nitrocellu-
lose glass ONCYTE slides. As controls, the following purified
recombinant antigens expressed in yeast or E. coli were printed
onto the array in two dilutions (0.1 and 0.3 mg/ml): Sm-TSP-2
(Smp_181530), Sm29 (Smp_072190), Sj-TSP-2/238 (NCBI
ABQ44513) and Sj silencer (NCBI AAP06461). Non-schistosome
control proteins/RTS reactions were also spotted onto the
microarray as described [38], and included Epstein Barr virus
protein EBNA-1 as well as purified human immunoglobulins. The
printed in vitro expressed proteins were quality checked using
antibodies against incorporated N-terminal poly-histidine (His)
and C-terminal hemagluttinin (HA) tags. The efficiency for in vitro
expression was higher than 95%, where positive features were
considered to have detectable His or HA tags (Figure S1).
Probing of protein microarrays with human sera
Sera were pre-adsorbed for anti-E. coli antibodies by rocking for
30 min at RT with E. coli lysate before probing of arrays. Protein
arrays were blocked in blocking solution (Maine Manufacturing)
for 2 hours at RT prior to probing with human sera (diluted 1:50)
at 4uC overnight with gentle constant rocking [71]. Arrays were
washed 3 times for 5 min with TBS/0.05% Tween 20 (TTBS)
then isotype and subclass specific responses were detected using
biotinylated monoclonal antibodies against human IgG1, IgG3,
IgG4 (Sigma) and IgE (Hybridoma Reagent Laboratory, Balti-
more, MD) diluted 1:100 for 2 h at RT. Arrays were washed again
then incubated for 2 h in streptavidin Cy-5 diluted 1:400 and
washed with TTBS followed by TBS then MQ water, 365 min in
each solution. Air-dried slides were scanned on a Genepix 4200AL
scanner (Molecular Devices) and signal intensities (SI) quantified
using the ScanArray Express Microarray Analysis System Version
3.0 (Molecular Devices). Raw SI were corrected for spot-specific
background using the Axon GenePix Pro 7 software. Data were
analyzed using the ‘‘group average’’ method [78] whereby the
mean SI was considered for analysis. Briefly, the SI for negative
control spots (empty vector) was calculated for each serum and
each antibody type. This value was considered as the background
and was subtracted from the SI of each protein spot. To determine
if an antigen was recognized a cut-off for each antibody type was
defined. The cut offs were defined as one standard deviation above
the average of the negative control spots for all groups of sera
(Negative BZL, Negative USA, PR, CI-Light, CI-Mod, CI-Heavy)
after correcting for spot-specific background. The cut offs were-
IgE: 2828.8; IgG4: 2767.3; IgG3: 1557; and IgG1: 316.4.
Spatial projection and clustering analysis
All 217 RTS proteins as well as purified E. coli-derived Sm29
and yeast-derived Sm-TSP-2 were used to conduct a spatial
analysis. When mean SI was below the cut-off for a given antibody
isotype/subclass, the SI value was adjusted to zero for this analysis
only. To identify clusters containing proteins with the same
antibody reactivity profiles we generated a distance matrix
estimated from the pairwise Euclidian distance of log transformed
SI for each antigen based on the cut-off values for each antibody
isotype/subclass in the different cohorts. Complete linkage
clustering methodology was used to create a dendrogram analysis





( log ( fiap){ log ( fjap))
Where D(i,j) represents the distance between the proteins i and j,
E is the antibody isotypes (IgG1, IgG3, IgG4 and IgE) and S is the
set of individual subjects; f iap is the fluorescence signal relative to
antibody isotype present in the serum of subject p reactive against
protein i; f jpa is the fluorescence signal for the same sample against
protein j. To provide a visual representation of each distance
matrix, we used a multidimensional scaling (MDS) plot with two
dimensions (2D). The unsupervised methodology k-means algo-
rithm with 1,000 interactions [40] was used to define seven
clusters. Clusters were validated using clValid, a R software
package for cluster validation [79]. The distance matrix, MDS,
clustering and graphing were performed using the R software
platform (www.r-project.org) [80]. Graphics representing specific
relativities that characterized each cluster were designed using
GraphPad Prism 5.0. The raw SI values grouped into clusters are
provided in Table S2.
Statistical analyses
Kruskal-Wallis with Dunn’s multiple comparison test was used
to compare more than two independent samples (Figure 1) and to
calculate the statistical differences between the groups if the
protein was classified as reactive (Figures 2–5). Correlations were
calculated using the Spearman Test. Statistical analyses were
performed with GraphPad Prism 5.0.
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Supporting Information
Figure S1 Quality control probing of the schistosome
protein array with anti-6His and anti-HA antibodies.
Control proteins on the array are denoted by colored boxes and
the corresponding key at the bottom of the image. Schistosoma
proteins correspond to spots present inside the orange dashed
lines. Other proteins on the array that are not contained within
boxes are hookworm proteins that are not considered within the
context of this study.
(EPS)
Figure S2 Consistent IgG1 immunoreactivity of all
cohorts to the Epstein Barr virus EBNA-1 protein. IgG1
response was evaluated in all subjects to EBNA-1 protein spotted
at a concentration of 0.1 mg/ml (upper panel) and 0.3 mg/ml
(lower panel) on the protein array. Negative BZL control (Neg-
BZL), Putative Resistant (PR), chronically infected with S. mansoni
at low (CI-Light), moderate (CI-Mod) and high (CI-Heavy)
infection intensities. Red line is the cut-off calculated by the
average of the signal intensity plus one standard deviation of the
no-DNA control spots present on the array.
(EPS)
Figure S3 Anti-soluble worm antigen preparation
(SWAP) IgG subclass responses. ELISA was performed by
coating microtiter plates with SWAP and probing with sera from
the different cohorts followed by subclass specific secondary
antibodies. Negative Brazilian controls from a non-endemic area
for schistosomiasis (BRZ-Neg), Putative Resistant (PR), chronically
infected with S. mansoni at low (CI-Light), moderate (CI-Mod) and
high (CI-Heavy) infection intensities.
(TIF)
Figure S4 Developmental expression of Sm-cam-3
(Smp-139970) and its S. japonicum ortholog (contig8758)
during the schistosome lifecycle, as obtained from
public databases. (A) Left: developmental expression of S.
japonicum contig8758 [60]; Middle: developmental expression of S.
mansoni TC16561 ( = Smp-139970) during the cercaria to schisto-
somulum transformation determined by microarray analysis [61];
Right: developmental expression of Smp_139970 in S. mansoni
during the cercaria to lung-stage schistosomulum transformation
determined by RNA Seq reads [81]. Mira: miracidia, Sporo:
sporocysts, Cerc: cercariae, Lung: 3 day lung schistosomula, M4-
6-7: adult males from mice at 4-6-7 weeks post cercarial challenge,
F4-6-7: adult females from mice at 4-6-7 weeks post cercarial
challenge, 3-5-24 hr: 3-5-24 hr schistosomula post mechanical
transformation of cercariae, Adults: mixed male and female adults
from mice. (B) Multiple sequence alignment of Sm-CAM-3 with its
closest homologues from S. mansoni (Sm-CAM-4; NCBI
XP_002574739) and non-human primates (Macaca mulatta cal-
modulin; NCBI EHH18861).
(TIF)
Figure S5 Correlations between IgG4 and IgE responses
in each different cohort of schistosome exposed individ-
uals. Dots represent the mean signal intensity per reactive protein
within each group. Correlations were performed using linear
regression (color coded solid lines and r2 values as indicated) and
95% confidence intervals are denoted by dashed lines. Groups are
putative resistant (PR), S. mansoni chronically infected with low (CI-
low), moderate (CI-Mod) and heavy (CI-Heavy) intensity
infections.
(TIF)
Figure S6 Dendrogram showing the multi-dimensional
clustering of immunoreactive proteins. Multi-dimensional
clustered distribution of all proteins according to the antibody
isotype/subclass responses in distinct cohorts. Proteins formed 7
clusters, defined by the following colors: cluster 1 - black (4
proteins); cluster 2 – blue (11 proteins); cluster 3 – grey (5 proteins);
cluster 4 – green (31 proteins); cluster 5 – magenta (47 proteins);
cluster 6 – orange (11 proteins) and cluster 7 – red (106 proteins).
(TIF)
Table S1 List of antigens printed with annotation and
protein sequences.
(XLSX)
Table S2 List of immunoreactive proteins divided and
color-coded by clusters according to the multi-dimen-
sional cluster analysis (Figure S5).
(XLSX)
Table S3 List of immunoreactive proteins by isotype.
(XLSX)
Table S4 Statistical analyses for all immunoreactive
proteins divided by isotype/subclass.
(XLSX)
Table S5 Spearman correlations between isotype/sub-
class specific antibody responses.
(XLSX)
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